GUTS
$0.46
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
Intraday
Recent News
Fractyl Health, Inc. (GUTS) Moves to Buy: Rationale Behind the Upgrade
Fractyl Health, Inc. (GUTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fractyl Health, Inc. (GUTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fractyl Health (GUTS) Tests Whether Revita Can Redefine Post-GLP-1 Weight Maintenance Economics
Fractyl Health has reported positive six-month randomized results from the REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study of its Revita procedure for weight maintenance after GLP-1 drug discontinuation, and is seeking FDA feedback on a potential De Novo regulatory pathway. The company has laid out a packed 2026 roadmap of clinical readouts and regulatory milestones for Revita, signaling a clearer path toward potential U.S. marketing submission in post-GLP-1 weight maintenance. We...
Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain
Fractyl Health (NASDAQ:GUTS) presented prospective, randomized, double-blind, controlled six-month data from its REMAIN-1 midpoint cohort pilot study, highlighting results the company said support Revita’s ability to help patients maintain weight loss after discontinuing GLP-1 therapy. Management al
BC-Most Active Stocks
Kosmos Energy Ltd. 24,086,956 1.72